Building Authority in Regulatory Affairs: How We Created a Content Ecosystem for a Complex B2B Market

Content Marketing

The Problem

NuMantra operates in one of the most technically demanding corners of B2B software: regulatory affairs automation. Their audience (VPs and Directors of Regulatory Affairs at biotech and pharma companies) is tasked with managing FDA submissions, eCTD compliance, and clinical dossiers. These are high-stakes, highly specialised workflows where a single error can delay approvals by months or cost millions.

When Justwords came in, NuMantra already had early traction. The problem was authority. To rank, convert, and become the trusted resource in this space, they needed content to prove they understood the actual anxiety, the real complexities, and the trade-offs that regulatory teams face every day.

Most SaaS companies in regulated industries default to safe, surface-level content. We saw an opportunity to go deep, get specific, and build genuine expertise on the page.

The Challenge: Complexity Without Compromise

Regulatory affairs is not a space where you can fake knowledge. A blog post that misunderstands FDA Module 3 requirements or treats eCTD 4.0 validation superficially just performs poorly; it damages trust. The audience is experienced enough to spot bullshit. They are also under enough pressure that they need answers they can actually rely on.

We faced three core challenges:

Domain Expertise Gap
The writers, editors, reviewers and strategists on the project needed to become fluent in pharmaceutical regulatory workflows. They needed to be genuinely capable of explaining the difference between a 505(b)(1) and 505(b)(2) NDA pathway, or why Module 3 CMC data structure matters for submission timelines. This meant investing time in understanding FDA guidance documents, ICH specifications, and the regulatory ecosystem itself. There were no shortcuts.
Audience Specificity
Regulatory affairs is a niche within a niche. The ICP isn’t “pharma companies.” It’s VPs and Directors personally responsible for submission timelines, under budget pressure, and sceptical of AI hype. They needed content that spoke to their reality like manual processes, compressed timelines, and the cost of errors. Generic “how to automate your workflow” wouldn’t land. We needed to address the specific pain points they were living with.

Information Architecture at Scale
A single blog post on eCTD submissions isn’t enough. The regulatory ecosystem is layered: eCTD structure (Module 1–5), regional differences (FDA vs. EMA vs. Health Canada), submission types (IND vs. NDA vs. BLA), and emerging concerns (eCTD 4.0 transition, AI in pharmacovigilance). We needed to build a content architecture that covered this complexity whilst remaining navigable – pillars that connected, checklists that gated traffic, thought leadership that established authority.

The Strategy: Three Pillars, One Unified Ecosystem

We built a content ecosystem organised around three strategic pillars, each addressing a different facet of the regulatory workflow:

Pillar A:

eCTD Regulatory Compliance

The foundation. This pillar covers the technical backbone of drug submissions: eCTD structure, module-by-module guidance, validation processes, and the upcoming eCTD 4.0 transition. Articles here are detailed, practical, and directly solve immediate problems.

Examples include deep dives into Module 3 CMC structure, eCTD validation checklists, and step-by-step workflows for small biotech teams. The content here ranks on high-intent, problem-solving keywords. CTAs drive towards demos and downloadable checklists, thereby moving prospects into consideration.

Pillar B:

IND/NDA/BLA Submission Strategy

This pillar addresses the full submission lifecycle: IND readiness, NDA vs. BLA pathway selection, pre-submission meeting prep, and handling FDA rejections. These are the conversations VPs are actually having, like “What do we need before we file an IND?” “How do we respond to a Complete Response Letter?”

Content here is written for decision-makers. It’s not just technical; it’s strategic. It connects regulatory workflows to business timelines and budget implications. Some articles are gated, which help converting high-intent traffic into leads.

Pillar C:

AI and Regulatory ROI

This pillar addresses the scepticism head-on. Many regulatory teams are evaluating AI and automation tools, but they are cautious. They want proof, not hype. Articles here cover real use cases in pharmacovigilance, build business cases for regtech investment, and honestly discuss what AI can and cannot do in regulatory workflows.

This is where thought leadership lives. Articles positioning the company as an informed, sceptical voice rather than a hype machine. CTAs here focus on cost calculators and demos, thus moving prospects from awareness to evaluation.

The Execution: Writing at Scale Without Losing Precision

The real test was execution. We needed to produce 20+ articles monthly whilst maintaining accuracy and depth in a highly technical domain.

Information Architecture First

Before a single article was written, we mapped the entire regulatory ecosystem. We identified 80+ potential content angles across the three pillars, mapped them to search intent, and sequenced them strategically. Early content established foundational knowledge; later content built on it. Internally, we linked aggressively. Each article referenced and supported others, creating topical clusters that Google recognises as authoritative coverage.

Editorial Standards That Held

We established non-negotiable standards:

- Every claim about FDA guidance had to be verified against official FDA or ICH documentation.
- Every article had to pass the “utility test” – would a busy VP actually use this to solve a problem?
- Tone was intentionally neutral. We described processes, not endorsed them. We acknowledged complexity and trade-offs rather than smoothing over them.
- No AI-generated content. Every article was researched and written by specialists with genuine domain understanding.

Keyword Strategy Aligned with User Intent

We didn’t optimise for keywords alone. We optimised for intent. A keyword like “eCTD Module 3 CMC guide biotech” signals that someone is actively preparing a submission and needs practical, implementable guidance. We built articles around that intent rather than around keyword density.

Gated Assets as Conversion Levers

We identified some high-intent topics like IND readiness checklists, CMC submission playbooks, and eCTD validation frameworks, and created gated PDF versions. These weren’t marketing collateral disguised as guides; they were expanded, implementable frameworks that captured leads from teams actively evaluating the platform.

What We Built

Over the course of the engagement, we developed:

- 20+ evergreen articles per month across three strategic pillars, each 1,800–3,000 words, targeting high-intent regulatory keywords. This was sustained across multiple writers without compromising quality.
- An extended content bank of additional articles, mapped to emerging use cases and seasonal regulatory cycles.
- Gated assets directly driving lead capture: checklists, playbooks, and frameworks.
- A unified internal linking strategy creating topical clusters that signal authority to search engines.
- Editorial guidelines ensuring every piece maintained domain accuracy and audience specificity.

The result was a knowledge base designed to serve regulatory teams at every stage of their journey, from initial awareness (“What is eCTD 4.0?”) to active consideration (“How do we respond to a CRL?”) to evaluation (“What does a modern regulatory tech stack look like?”).

The Outcome

We built a content ecosystem that served as a credible, reference-quality resource for one of the most technically demanding B2B markets. The content didn’t pretend to be simple. It didn’t oversell AI. It didn’t avoid complexity. Instead, it embraced it, explained it, and provided users with frameworks to navigate it.

The engagement demonstrated that even in highly specialised, regulated industries, thoughtful content strategy can establish authority and drive meaningful engagement when it’s grounded in genuine domain understanding, structured around user intent, and executed with precision.

VPs and Directors responsible for regulatory submissions aren’t looking for marketing copy. They are looking for a resource that understands their world. We built that.

Why This Approach Worked

Specificity Over Breadth
We didn’t try to be a resource for “pharma” or “biotech.” We made NuMantra a resource for regulatory affairs professionals managing specific, high-stakes workflows. That focus meant every article had a clear user, a clear problem, and a clear answer.

Depth as Differentiation
In a space where most competitors default to surface-level “thought leadership,” going deep on module structures, FDA guidance, and implementation workflows became a genuine differentiator. VPs bookmarked these articles. Teams referenced them during submissions. That’s engagement money can’t buy.

Architecture Over Isolation
A single excellent article ranks. A pillar of 15 interconnected articles that cover a topic from multiple angles, serve different audiences, and link coherently? That establishes topical authority. Search engines notice. Users notice. Conversion compounds.

Honesty About Complexity
Regulatory affairs is complex. Rather than oversimplifying, we leaned into that. We acknowledged where FDA guidance was ambiguous. We discussed trade-offs between different submission strategies. We were honest about what AI could and couldn’t do. That honesty built trust in a space where trust is currency.